|
IST
GV Prasad, VC & CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
Its Q4 consolidated net sales were at Rs 1,320 crore versus Rs 1,557.3 crore(US GAAP).
The company's FY08 consolidated net profit stood at Rs 470 crore. DRL Q4FY07 numbers included Zofran Exclusivity (Rs 270 crore).
GV Prasad, Vice Chairman and CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, , which involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
Reditux launched in India and is showing good growth, the management added.
For complete conference, watch video...
Set email alert for Tags: Dr Reddys Laboratories , GV Prasad
|
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
Dr Reddys Laboratories 
